Fate Therapeutics Secures Up to $20 Million in Debt Financing

"This debt financing further secures the necessary cash resources to clinically validate our lead product candidate PROHEMA across multiple disease franchises including adult and pediatric patients with hematologic malignancies and pediatric patients with inherited metabolic disorders," said "The additional capital also enables the Company to ... (more)

http://ift.tt/1uMJvJt